Results 161 to 170 of about 35,200 (254)

P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. [PDF]

J Pathol, 2022
Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS.   +13 more
europepmc   +1 more source

What Role Does the Central Nervous System Play in Refractory LUTS, and What Are the Therapeutic Implications? ICI‐RS 2025

Neurourology and Urodynamics, Volume 45, Issue 5, Page 929-936, June 2026.
ABSTRACT Aims While many patients with lower urinary tract symptoms (LUTS) improve by treating peripheral causes, a substantial proportion continue to experience symptoms despite apparently successful interventions. Central nervous system (CNS) mechanisms could potentially contribute to persisting symptoms after the initial peripheral cause has been ...
Mathijs M. de Rijk, Michel Wyndaele, Ana Charrua, Christopher Fry, Paul Abrams, Gommert A. van Koeveringe, Anthony J. Kanai, Marcus J. Drake   +7 more
wiley   +1 more source

P2X7 Receptor Modulation of Visual Responses in the Retina

, 2015
Adenosine 5’ triphosphate (ATP)-gated P2X7 receptors (P2X7Rs) are known to act as conduits for photoreceptor and retinal ganglion cell (RGC) damage, consequences of various neurodegenerative conditions within the visual pathway. Growing evidence supports
Chavda, S
core  

Control of Macrophage Inflammation by P2Y Purinergic Receptors. [PDF]

Cells, 2021
Klaver D, Thurnher M.
europepmc   +1 more source

Purinergic Receptor [PDF]

, 2020
openaire   +1 more source

Clopidogrel, an ADP‐P2Y12 Receptor Antagonist, Is Associated With Lower Opioid Consumption and a Reduced Incidence of Delirium in Cancer Patients Receiving Chemotherapy: A Nationwide Retrospective Cohort Study in Japan

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Clopidogrel use was associated with reduced opioid consumption, lower use of other analgesics, and a decreased incidence of hyperactive delirium compared with aspirin in cancer patients receiving chemotherapy, suggesting a potential analgesic effect possibly linked to P2Y12 receptor inhibition.
Hiroaki Abe, Reo Inoue, Takamichi Kogure, Rikuhei Tsuchida, Hiroaki Owada, Yoshika Sudo, Yaeko Yokoshima, Hiroki Matsui, Hideo Yasunaga, Masahiko Sumitani   +9 more
wiley   +1 more source

Molecular and Pharmacological Evidence for the Expression of Multiple Functional P2 Purinergic Receptors in Human Adipocytes. [PDF]

Molecules, 2022
Rossato M, Favaretto F, Granzotto M, Crescenzi M, Boscaro A, Di Vincenzo A, Capone F, Dalla Nora E, Zabeo E, Vettor R.   +9 more
europepmc   +1 more source

G Protein‐Coupled Receptor 17 (Gpr17) Enhances Leptin and Insulin Sensitivity in Lean and Obese Mouse Models

Obesity, Volume 34, Issue S1, Page 77-87, June 2026.
This study identifies G protein‐coupled receptor 17 (Gpr17) as a novel regulator of leptin and insulin sensitivity. Using complementary knockout models, we demonstrate that Gpr17 deletion enhances energy expenditure, restores leptin responsiveness, and improves insulin sensitivity, revealing Gpr17 as a potential therapeutic GPCR target for obesity and ...
Xun Sun, Connor Mahler, Natalie D. Stull, Ali Nasiri, Baohua Zhou, Varman Samuel, Gerald Shulman, Jonathan N. Flak, Hongxia Ren   +8 more
wiley   +1 more source

Blocking microglial reactivity via purinergic receptors prevents subacute cognitive deficits after TIA. [PDF]

EMBO Mol Med
Llovera G, Heindl S, Varga DP, Lenart N, Kallabis S, Göb V, Stegner D, Escaig R, Nicolai L, Franzmeier N, Meissner F, Denes A, Liesz A.   +12 more
europepmc   +1 more source

Adipocyte purinergic receptors activated by uracil nucleotides as obesity and type 2 diabetes targets. [PDF]

Curr Opin Pharmacol, 2022
Jain S, Jacobson KA.
europepmc   +1 more source